Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)
Squamous Cell Carcinoma of the Skin
DRUG: Nivolumab|DRUG: Nivolumab plus Relatlimab
Objective Response Rate (ORR), using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment, up to 5 years
Disease Control Rate (DCR), Disease Control Rate (DCR) using Response Criteria in Solid Tumors version 1.1 (RECIST1.1) per site assessment, up to 5 years|Duration of Response (DOR) in patients who achieve partial response (PR) or better, up to 5 years|Progression Free Survival (PFS), up to 5 years|Overall Survival (OS), up to 5 years|ORR and DCR for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression of tumor-infiltrating cells, up to 5 years|Number and severity of adverse events, up to 5 years|DOR, PFS and OS for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression of tumor-infiltrating cells, up to 5 years
To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)